Skip to main content
main-content

Medications

Highlights

01-02-2019 | Canagliflozin | medwireNews | News

No fracture risk found with canagliflozin in real-world data

Research based on insurance claims data indicates that new users of the sodium-glucose cotransporter-2 inhibitor canagliflozin are no more likely to experience a fracture than new users of glucagon-like peptide-1 receptor agonists.

Source:

Ann Intern Med 2019; doi:10.7326/M18-0567
Ann Intern Med 2019; doi:10.7326/M18-3550

12-19-2018 | Insulin degludec | Highlight | News

Real-world data show benefits of insulin degludec vs glargine in type 2 diabetes

Insulin-naive adults with type 2 diabetes derive greater benefit from treatment with insulin degludec than from insulin glargine 300 units/mL, results from the US clinical practice-based CONFIRM study show.

Source:

Diabetes Obes Metab 2018; doi:10.1111/dom.13616

12-07-2018 | DPP-4 inhibitors | medwireNews | News

Possible bile duct cancer risk with incretin-based medications

Data from clinical practice suggest the possibility of an increased relative risk for cholangiocarcinoma among patients taking incretin-based antidiabetes medications, although the absolute risk remains small.

Source:

BMJ 2018; 363: k4880
BMJ 2018; 363: k5155

12-03-2018 | Liraglutide (T2DM) | medwireNews | News

Older type 2 diabetes patients may derive greatest liraglutide benefits

The LEADER investigators report that treatment with the glucagon-like peptide-1 receptor agonist liraglutide may be of particular benefit in the oldest patients with type 2 diabetes.

Source:

Ann Intern Med 2019; doi:10.7326/M18-1569

11-20-2018 | Insulin | Highlight | News

Research predicts ‘highly inadequate’ insulin access in coming years

A modeling study predicts a greater than 20% increased need for insulin to treat patients with type 2 diabetes over the next 22 years, with implications for medication access.

Source:

Lancet Diabetes Endocrinol 2018; doi:10.1016/S2213-8587(18)30303-6
Lancet Diabetes Endocrinol 2018; doi:10.1016/S2213-8587(18)30312-7

11-10-2018 | Dapagliflozin | Highlight | News

DECLARE-TIMI 58 supports CV benefits of SGLT2 inhibitor class

The results of the DECLARE-TIMI 58 trial show a broadly positive effect of dapagliflozin on cardiovascular outcomes, especially heart failure, in patients with type 2 diabetes.

Source:

N Engl J Med 2018; doi:10.1056/NEJMoa1812389

11-06-2018 | Cardiovascular outcomes | Highlight | News

Type 2 diabetes, polyvascular disease combine to increase cardiovascular risk

Type 2 diabetes and polyvascular disease are additive risk factors for cardiovascular events in patients with acute coronary syndromes, a secondary analysis of the IMPROVE-IT trial suggests.

Source:

Lancet Diabetes Endocrinol 2018; doi:10.1016/S2213-8587(18)30290-0
Lancet Diabetes Endocrinol 2018; doi:10.1016/S2213-8587(18)30311-5

10-22-2018 | Mental health | Highlight | News

Insulin manipulation strongly linked to psychiatric comorbidity

Insulin manipulation, the practice of deliberately under- or overdosing insulin, is strongly associated with psychiatric comorbidity in children and young adults with type 1 diabetes, Austrian research shows.

Source:

Pediatr Diabetes 2018; doi:10.1111/pedi.12784

10-04-2018 | Empagliflozin | EASD 2018 | News

EASE: Add-on empagliflozin improves glycemic control in type 1 diabetes

The addition of empagliflozin to insulin therapy reduces glycated hemoglobin levels in patients with type 1 diabetes, indicate findings from the phase III EASE-2 and 3 trials.

Source:

Diabetes Care 2018; doi:10.2337/dc18-1749
EASD Annual Meeting; Berlin, Germany: 1–5 October 2018

10-04-2018 | GLP-1 agonists | EASD 2018 | News

Promising phase II data for dual GIP and GLP-1 receptor agonist

A compound that stimulates the receptors for both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 has dose-dependent effects on glucose levels and bodyweight in people with type 2 diabetes.

Source:

Lancet 2018; doi:10.1016/S0140-6736(18)32260-8
Lancet 2018; doi:10.1016/S0140-6736(18)32466-8
EASD Annual Meeting; Berlin, Germany: 1–5 October 2018

10-03-2018 | Lixisenatide | EASD 2018 | News

Lixisenatide may lessen albuminuria progression in type 2 diabetes

Macroalbuminuric patients with type 2 diabetes and a recent acute coronary event who are treated with lixisenatide may experience a reduction in their urinary albumin-to-creatinine ratio, suggests an exploratory post-hoc analysis of the ELIXA trial.

Source:

Lancet Diabetes Endocrinol 2018; doi:10.1016/S2213-8587(18)30268-7

Lancet Diabetes Endocrinol 2018; doi:10.1016/S2213-8587(18)30291-2

EASD Annual Meeting; Berlin, Germany: 1–5 October 2018

10-02-2018 | Albiglutide | EASD 2018 | News

Albiglutide reduces cardiovascular risk in patients with type 2 diabetes

Results of the Harmony Outcomes trial indicate that adding the glucagon-like peptide-1 receptor agonist albiglutide to standard care may reduce cardiovascular risk among patients with type 2 diabetes and existing cardiovascular disease.

Source:

Lancet 2018; doi:10.1016/S0140-6736(18)32261-X
Lancet 2018; doi:10.1016/S0140-6736(18)32348-1
EASD Annual Meeting; Berlin, Germany: 1–5 October 2018

09-30-2018 | UKPDS | Feature | Article

The UKPDS: A lasting legacy

Twenty years after the publication of the primary findings, medwireNews talks to longtime UKPDS investigator Professor David Matthews (University of Oxford, UK) about the struggles of the team to bring the trial to completion and the impact of the findings on diabetes care.

09-18-2018 | Sexual dysfunction | View from the clinic | Article

Regaining sexual health in diabetes: Start with open communication

Advisory Board member Clipper Young recounts an experience of starting a patient with erectile dysfunction on the path to appropriate treatment for him and his diabetes.

Author:
Clipper Young

09-17-2018 | Prediabetes | medwireNews | News

Targeting pathophysiology from outset may slow progression to type 2 diabetes

Upfront treatment with medications that target the underlying pathophysiology of prediabetes may slow patients’ progression to type 2 diabetes, report researchers.

Source:

Lancet Diabetes Endo 2018; doi:10.1016/S2213-8587(18)30234-1
Lancet Diabetes Endo 2018; doi:10.1016/S2213-8587(18)30267-5

08-18-2018 | Continuous glucose monitoring | Review | Article

Prevention and management of severe hypoglycemia and hypoglycemia unawareness: Incorporating sensor technology

Lucidi P et al. Curr Diab Rep 2018; 18: 83. doi: 10.1007/s11892-018-1065-6

09-05-2018 | Diagnosis | Case study | Article

Acute illness while on a SGLT2 inhibitor and ketogenic diet

Advisory Board member Theresa Smyth tackles an emergency case in a type 2 diabetes patient treated with empagliflozin. What went wrong and how should he be managed?

Author:
Theresa Smyth

08-31-2018 | Medications | Highlight | News

Poor availability, affordability compromise global diabetes medication use

Diabetes medications are frequently unavailable and unaffordable, particularly in lower-income countries, shows an analysis of the PURE study.

Source:

Lancet Diabetes Endocrinol 2018; doi:10.1016/S2213-8587(18)30233-X

08-26-2018 | Lorcaserin | Highlight | News

Neutral cardiovascular safety for lorcaserin in CAMELLIA-TIMI 61

The weight-loss medication lorcaserin neither increases nor reduces cardiovascular risk, report the CAMELLIA–TIMI 61 investigators.

Source:

N Engl J Med 2018; doi:10.1056/NEJMoa1808721
N Engl J Med 2018; doi:10.1056/NEJMe1810855

05-02-2018 | Insulin | Editorial | Article

Glycemic goal setting in type 1 diabetes: Time to get SMART in the clinic?

Diabetes and endocrinology Consultant and Advisory Board member Terence Pang highlights the benefits that a structured approach to glycemic goal setting can bring to your practice and patients with type 1 diabetes.

Author:
Terence Pang
image credits